WINSTON-SALEM, N.C.--(EON: Enhanced Online News)--Targacept Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced it will report financial results for the third quarter of 2013 on Tuesday, November 5, 2013, before the U.S. financial markets open.
Management will discuss Targacept’s financial results, provide a business and program update, and discuss expectations for the future via conference call at 8:30 a.m. Eastern Time on Tuesday, November 5, 2013. The conference call may be accessed by dialing 866.318.8618 for domestic participants and 617.399.5137 for international callers (reference passcode 21126805). A replay of the call may be accessed beginning approximately two hours after its conclusion and continuing through November 19, 2013 by dialing 888.286.8010 for domestic callers and 617.801.6888 for international callers (reference passcode 87233505).
A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available for replay via the Investor Calendar section of the Investor Relations page of Targacept’s website for at least two weeks following the call.
Targacept is developing an advanced clinical pipeline of NNR Therapeutics™ to treat patients suffering from serious nervous system and gastrointestinal/genitourinary diseases and disorders. Many diseases arise from abnormalities in signaling within and between the brain and other organ systems such as the bladder and the GI tract. Targacept’s NNR Therapeutics have the potential to normalize these signaling pathways to provide significant medical benefit. Targacept is dedicated to building health and restoring independence for patients. For more information, please visit www.targacept.com.
Building Health, Restoring Independence®